IL244506B - A sodium channel modulator for the treatment of pain and diabetes - Google Patents
A sodium channel modulator for the treatment of pain and diabetesInfo
- Publication number
- IL244506B IL244506B IL244506A IL24450616A IL244506B IL 244506 B IL244506 B IL 244506B IL 244506 A IL244506 A IL 244506A IL 24450616 A IL24450616 A IL 24450616A IL 244506 B IL244506 B IL 244506B
- Authority
- IL
- Israel
- Prior art keywords
- diabetes
- pain
- treatment
- sodium channel
- channel modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876046P | 2013-09-10 | 2013-09-10 | |
| PCT/US2014/054764 WO2015038533A2 (en) | 2013-09-10 | 2014-09-09 | Sodium channel modulators for the treatment of pain and diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL244506A0 IL244506A0 (en) | 2016-04-21 |
| IL244506B true IL244506B (en) | 2020-02-27 |
Family
ID=52666496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL244506A IL244506B (en) | 2013-09-10 | 2016-03-09 | A sodium channel modulator for the treatment of pain and diabetes |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20160221974A1 (Direct) |
| EP (1) | EP3043787B1 (Direct) |
| JP (1) | JP6445565B2 (Direct) |
| KR (1) | KR20160054570A (Direct) |
| CN (1) | CN105611923B (Direct) |
| AU (1) | AU2014318979B2 (Direct) |
| BR (1) | BR112016005271A2 (Direct) |
| CA (1) | CA2922851C (Direct) |
| ES (1) | ES2687598T3 (Direct) |
| IL (1) | IL244506B (Direct) |
| MX (1) | MX2016002881A (Direct) |
| MY (1) | MY181928A (Direct) |
| PH (1) | PH12016500296A1 (Direct) |
| RU (1) | RU2016113156A (Direct) |
| SG (2) | SG10201805552PA (Direct) |
| UA (1) | UA120353C2 (Direct) |
| WO (1) | WO2015038533A2 (Direct) |
| ZA (1) | ZA201702410B (Direct) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6449845B2 (ja) | 2013-03-15 | 2019-01-09 | クロモセル コーポレイション | 疼痛の処置のためのナトリウムチャネルモジュレーター |
| KR20160054570A (ko) | 2013-09-10 | 2016-05-16 | 크로모셀 코포레이션 | 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자 |
| JP2017527573A (ja) * | 2014-09-09 | 2017-09-21 | クロモセル コーポレーション | 糖尿病の治療用の選択的ＮａＶ１．７阻害剤 |
| JP6572392B2 (ja) | 2015-12-18 | 2019-09-11 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおいて選択的活性を有する、ヒドロキシアルキルアミンおよびヒドロキシシクロアルキルアミンで置換されたジアミン−アリールスルホンアミド化合物 |
| JP6938545B2 (ja) | 2016-05-20 | 2021-09-22 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
| CN105924670A (zh) * | 2016-06-02 | 2016-09-07 | 扬州兰都塑料科技有限公司 | 一种电力电缆用耐磨剂 |
| CN106084535A (zh) * | 2016-06-02 | 2016-11-09 | 扬州兰都塑料科技有限公司 | 一种耐刮擦的电力电缆的制备方法 |
| CN105924843A (zh) * | 2016-06-02 | 2016-09-07 | 扬州兰都塑料科技有限公司 | 一种耐刮擦的电力电缆 |
| TN2019000175A1 (en) | 2016-12-09 | 2020-10-05 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| CN106892845B (zh) * | 2017-02-28 | 2018-10-30 | 四川同晟生物医药有限公司 | 一种2,4-二氨基丁酸衍生物及其制备方法 |
| WO2019200369A1 (en) * | 2018-04-13 | 2019-10-17 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage |
| WO2019217822A1 (en) * | 2018-05-11 | 2019-11-14 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions |
| CR20200613A (es) | 2018-06-13 | 2021-06-10 | Xenon Pharmaceuticals Inc | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| EA202190395A1 (ru) | 2018-08-31 | 2021-06-15 | Ксенон Фармасьютикалз Инк. | Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств |
| CN113527281B (zh) * | 2020-04-20 | 2023-12-22 | 昆山彭济凯丰生物科技有限公司 | 杂环化合物及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| PL364388A1 (en) * | 2001-03-14 | 2004-12-13 | Grünenthal GmbH | Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| US7659082B2 (en) | 2002-02-19 | 2010-02-09 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
| BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| WO2005054202A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
| CA2564355C (en) | 2004-05-07 | 2012-07-03 | Amgen Inc. | Protein kinase modulators and method of use |
| CA2574600C (en) * | 2004-07-23 | 2010-08-31 | Pfizer Inc. | Pyridine derivatives |
| WO2006046916A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| US7622496B2 (en) * | 2005-12-23 | 2009-11-24 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
| AU2008213836A1 (en) * | 2007-02-05 | 2008-08-14 | Xenon Pharmaceuticals Inc. | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
| EP2175728B1 (en) | 2007-07-13 | 2014-09-10 | Icagen, Inc. | Sodium channel inhibitors |
| JP5460589B2 (ja) | 2007-07-13 | 2014-04-02 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| CA2747419C (en) * | 2009-01-12 | 2014-07-08 | Icagen, Inc. | Sulfonamide derivatives |
| CN105130957A (zh) | 2009-05-29 | 2015-12-09 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| WO2011133729A2 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Anti-viral compounds |
| ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| JP5860045B2 (ja) | 2010-07-09 | 2016-02-16 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化合物 |
| ES2533065T3 (es) | 2010-07-09 | 2015-04-07 | Pfizer Limited | Bencenosulfonamidas útiles como inhibidores de los canales de sodio |
| CA2804877A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| MX2013008282A (es) | 2011-01-18 | 2014-02-10 | Amgen Inc | Ratones con genes inactivados nav1.7 y usos. |
| UY34171A (es) * | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| US9079902B2 (en) | 2011-08-17 | 2015-07-14 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| US20140221286A1 (en) | 2011-09-21 | 2014-08-07 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| EP2773641B1 (en) | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| CA2890897A1 (en) | 2012-11-14 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt) |
| JP6449845B2 (ja) * | 2013-03-15 | 2019-01-09 | クロモセル コーポレイション | 疼痛の処置のためのナトリウムチャネルモジュレーター |
| ES2784454T3 (es) | 2013-09-09 | 2020-09-25 | Peloton Therapeutics Inc | Aril éteres y usos de los mismos |
| KR20160054570A (ko) | 2013-09-10 | 2016-05-16 | 크로모셀 코포레이션 | 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자 |
| JP2017527573A (ja) * | 2014-09-09 | 2017-09-21 | クロモセル コーポレーション | 糖尿病の治療用の選択的ＮａＶ１．７阻害剤 |
-
2014
- 2014-09-09 KR KR1020167009294A patent/KR20160054570A/ko not_active Ceased
- 2014-09-09 CN CN201480049690.8A patent/CN105611923B/zh not_active Expired - Fee Related
- 2014-09-09 AU AU2014318979A patent/AU2014318979B2/en not_active Ceased
- 2014-09-09 EP EP14843353.5A patent/EP3043787B1/en active Active
- 2014-09-09 ES ES14843353.5T patent/ES2687598T3/es active Active
- 2014-09-09 JP JP2016540921A patent/JP6445565B2/ja active Active
- 2014-09-09 SG SG10201805552PA patent/SG10201805552PA/en unknown
- 2014-09-09 CA CA2922851A patent/CA2922851C/en active Active
- 2014-09-09 US US15/021,153 patent/US20160221974A1/en not_active Abandoned
- 2014-09-09 UA UAA201603676A patent/UA120353C2/uk unknown
- 2014-09-09 MY MYPI2016700824A patent/MY181928A/en unknown
- 2014-09-09 BR BR112016005271-4A patent/BR112016005271A2/pt not_active IP Right Cessation
- 2014-09-09 SG SG11201601367QA patent/SG11201601367QA/en unknown
- 2014-09-09 RU RU2016113156A patent/RU2016113156A/ru not_active Application Discontinuation
- 2014-09-09 WO PCT/US2014/054764 patent/WO2015038533A2/en not_active Ceased
- 2014-09-09 MX MX2016002881A patent/MX2016002881A/es active IP Right Grant
-
2016
- 2016-01-13 US US14/994,846 patent/US9458118B2/en active Active
- 2016-02-12 PH PH12016500296A patent/PH12016500296A1/en unknown
- 2016-03-09 IL IL244506A patent/IL244506B/en active IP Right Grant
-
2017
- 2017-04-05 ZA ZA2017/02410A patent/ZA201702410B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160054570A (ko) | 2016-05-16 |
| SG11201601367QA (en) | 2016-03-30 |
| US20160221974A1 (en) | 2016-08-04 |
| WO2015038533A2 (en) | 2015-03-19 |
| WO2015038533A3 (en) | 2015-10-29 |
| BR112016005271A2 (pt) | 2020-05-12 |
| AU2014318979B2 (en) | 2019-03-28 |
| JP6445565B2 (ja) | 2018-12-26 |
| IL244506A0 (en) | 2016-04-21 |
| SG10201805552PA (en) | 2018-08-30 |
| PH12016500296A1 (en) | 2016-05-16 |
| UA120353C2 (uk) | 2019-11-25 |
| EP3043787A4 (en) | 2017-02-01 |
| US20160130239A1 (en) | 2016-05-12 |
| ZA201702410B (en) | 2019-06-26 |
| CN105611923B (zh) | 2019-08-23 |
| US9458118B2 (en) | 2016-10-04 |
| CA2922851A1 (en) | 2015-03-19 |
| AU2014318979A1 (en) | 2016-03-03 |
| CN105611923A (zh) | 2016-05-25 |
| EP3043787B1 (en) | 2018-09-05 |
| EP3043787A2 (en) | 2016-07-20 |
| RU2016113156A (ru) | 2017-10-16 |
| MY181928A (en) | 2021-01-14 |
| MX2016002881A (es) | 2016-04-21 |
| JP2016532716A (ja) | 2016-10-20 |
| ES2687598T3 (es) | 2018-10-26 |
| CA2922851C (en) | 2023-03-14 |
| RU2016113156A3 (Direct) | 2018-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201702410B (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| IL242564A0 (en) | Sodium channel modulators for pain management | |
| IL241026B (en) | A head device for treating and evaluating medical conditions | |
| HUE039560T2 (hu) | Mikro méretû zárófedés és kapcsolódó eljárások bõr kezelésére | |
| EP2967744A4 (en) | SKIN TREATMENT DEVICE | |
| PT2961269T (pt) | Dispositivo de depleção de gás para produtos sanguíneos | |
| PL2764881T3 (pl) | System leczenia medycznego | |
| IL238907A (en) | A device for treating depression, anxiety and pain | |
| EP2952149A4 (en) | THERAPEUTIC TREATMENT DEVICE | |
| SG11201509782TA (en) | Compositions and methods for the treatment of diabetes and pre-diabetes | |
| EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
| EP3019138A4 (en) | Guiding means for administering acupuncture and other healing procedures | |
| GB201602663D0 (en) | Medical instrument and application thereof | |
| GB201315887D0 (en) | Medical applicator | |
| PL2986333T3 (pl) | Medyczny aplikator na skórę | |
| IL235272B (en) | Alfentanil preparation for the treatment of acute pain | |
| GB201309375D0 (en) | Medical methods and compounds for medical use | |
| EP3104869A4 (en) | Treatment of pain | |
| GB201316738D0 (en) | Implantable Medical Devices | |
| SG11201510081UA (en) | Surface modification of medical or veterinary devices | |
| LT2992094T (lt) | I tipo diabeto gydymo būdai ir kompozicijos | |
| GB201410954D0 (en) | Skin treatment devices and methods | |
| GB201309376D0 (en) | Medical methods and compounds for medical use | |
| GB201309498D0 (en) | Novel diagnosis and therapy | |
| AU2013905080A0 (en) | Treatment of Pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted |